MK-677 (Ibutamoren)

MK-677, chemically known as ibutamoren, is a synthetic compound that mimics the action of ghrelin, the "hunger hormone." Despite being commonly grouped with peptides in research circles, it's technically a small molecule drug that activates the same receptor pathway. Originally developed by Merck in the 1990s for treating growth hormone deficiency and muscle wasting, MK-677 never reached market approval but found its way into research communities.\n\nWhat makes MK-677 unique among growth hormone research compounds is its oral bioavailability — most growth hormone-related substances require injection. The compound selectively binds to ghrelin receptors in the brain, triggering the body's natural growth hormone release cascade. Research interest centers on its potential effects on sleep quality, body composition, and recovery, though we emphasize that MK-677 is sold strictly for research purposes.\n\nThe compound's 24-hour half-life means once-daily dosing is sufficient, typically taken in the evening due to its tendency to increase appetite and promote deeper sleep phases. Users report effects beginning within 1-2 hours of oral administration.